Purinergic Signaling: A New Pharmacological Target
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".
Deadline for manuscript submissions: 25 June 2024 | Viewed by 509
Special Issue Editor
Special Issue Information
Dear Colleagues,
Proposed in 1972, purinergic signaling is characterized by the relationship between signaling components, receptors, and specific enzymes. The purinergic system is characterized by the action of extracellular nucleotides and nucleosides that are degraded by the action of several ectonucleotidases. ATP is an intracellular energy molecule, but it can be released from various types of cells after damage. Thus, after release, it can activate receptors or be rapidly decomposed by ectonucleotidases. Purinergic signaling receptors are classified into two main groups: P1 nucleoside receptor and P2 purinoceptor. All cells have components of the purinergic system and can release nucleotides in a controlled situation. The mechanisms related to the release of nucleotides have been an intense focus of research activities, and studies have extensively investigated the pharmacology and biochemistry of purinergic signaling. More recently, the focus has been on the therapeutic potential of components of the purinergic system, especially in relation to purinergic receptors. It is now established that changes in purinergic signaling are involved in the therapy of many diseases, in addition to being related to the effects of physical exercise and nutraceutical molecules on the body.
This Special Issue aims to present and discuss the advancement of research and innovative therapies involving the purinergic system and diseases with a high impact on society, such as diabetes, hypertension, atherosclerosis, heart disease, cancer, chronic kidney disease, neurological diseases such as epilepsy, neurodegenerative diseases such as Alzheimer’s, Parkinson’s, and multiple sclerosis, and the possibility of involving communicable and chronic emerging diseases. We solicit high-quality original research articles as well as review articles focused on the latest research and new findings on the immune system and chronic diseases, as well as the innovative mechanisms related to the development of an inflammatory process in chronic diseases.
Dr. Margarete Dulce Bagatini
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- purinergic receptors
- ectonucleotidases
- nucleotides
- nucleoside
